NTT-DATA
NTT DATA, a global leader in IT infrastructure and services, today announced a strategic partnership with Zebra Technologies, a leader in digital solutions, to accelerate innovation in the 5G device ecosystem, laying the foundation for widespread adoption across industries.
Under this multi-year agreement, NTT DATA and Zebra Technologies will co-innovate to drive the adoption of 5G devices, which is essential for Private 5G adoption. Together, the two companies will enable intelligent asset tracking that allows for real-time monitoring and management of assets in industrial and enterprise deployments, ensuring enhanced visibility, efficiencies, and security capabilities critical to Industry 4.0 supply chain management.
One critical barrier to Private 5G adoption has been the availability of 5G devices for enterprises. This partnership will bridge this gap for connected devices in the enterprise Private 5G market, which Omdia estimates will grow 35% globally over the next four years, reaching nearly $10 billion by 2028.
Empowering the Private 5G Device Landscape
The agreement establishes Zebra Technologies as a strategic partner within NTT DATA’s Device as a Service practice, making it easier for customers to access, upgrade, and simplify 5G device lifecycle management and support.
Available globally, customers will benefit from continual modernization of device deployments and the ability to harness new connectivity solutions with a leading suite of Wi-Fi, Private LTE, and Private 5G compatible devices.
This news follows NTT DATA’s recent collaboration with Qualcomm, aimed to accelerate the evolution of the 5G device ecosystem. With enterprises accelerating digital transformation, more connectivity is needed to support Industry 4.0 applications and the adoption of AI at the edge.
By leveraging NTT DATA’s Private 5G leadership and Zebra Technologies' expertise in intelligent data integration, asset management, and frontline coordination, the two companies aim to make the low latency and high-security features of Private 5G enabled devices easily accessible to frontline workers in the automotive, manufacturing, healthcare, and logistics industries.
“In our relentless pursuit to drive Private 5G and Edge AI adoption within the enterprises, we’re thrilled to join forces with Zebra Technologies globally,” said Shahid Ahmed, Group Executive Vice President, Edge Services at NTT DATA. “This alliance underscores our dedication to empowering enterprises with transformative capabilities that propel edge and Private 5G use cases and data-driven experiences.”
“Our partnership with NTT DATA underscores our commitment to bring customers the latest innovations powered by Wi-Fi, Private LTE, and Private 5G networks,” said Julie Johnson, Senior Vice President and General Manager of Enterprise Mobile Computing at Zebra Technologies. “We’re excited to leverage the global scale of NTT DATA’s capabilities to benefit our customers and be a vital part of a growing 5G device ecosystem, ensuring businesses can thrive in today’s rapidly evolving landscape.”
Elevating Network Deployment
NTT DATA is deploying a Private 5G network throughout Hyster-Yale Group’s manufacturing operations. Hyster- Yale Group is also leveraging NTT DATA’s Device as a Service to gain visibility into assets and materials and improve communications within its facilities. This network will work with Zebra Technologies’, handheld mobile computers and tablets to track assets and materials as they enter and exit manufacturing sites, providing critical business intelligence, while also seamlessly connecting engineers, onsite teams, production lines, and materials storage locations. All of this comes together through a cost-effective deployment at scale efficiently managed through NTT DATA’s Device as a Service practice.
“Adding Zebra devices to our Store Front has allowed us to procure units through our Device as a Service program with NTT DATA, offering much more SKU customization within a standard device set,” said Pierluigi Mastroddi, Director of IT Infrastructure Services at Hyster-Yale Group.
Benefits of Device as a Services Model
NTT DATA’s Device as a Service offers customers a comprehensive turnkey solution for managing the entire device lifecycle. It provides expert planning, procurement, configuration, deployment, ongoing support, analytics, repair management, and device retirement, all under the stewardship of a trusted partner. This allows customers to use a cost-effective per-user, per-month program model to consume technology products on a pay-per-user subscription basis instead of purchasing/owning the equipment.
About NTT DATA
NTT DATA is a $30+ billion trusted global innovator of business and technology services. We serve 75% of the Fortune Global 100 and are committed to helping clients innovate, optimize, and transform for long-term success. We invest over $3.6 billion each year in R&D to help organizations and society move confidently and sustainably into the digital future. As a Global Top Employer, we have diverse experts in more than 50 countries and a robust partner ecosystem of established and start-up companies. Our services include business and technology consulting, data and artificial intelligence, industry solutions, as well as the development, implementation and management of applications, infrastructure, and connectivity. We are also one of the leading providers of digital and AI infrastructure in the world. NTT DATA is part of NTT Group and headquartered in Tokyo. Visit us at nttdata.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240625541170/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Sonrotoclax Data at ASH 2025 Confirm Foundational Potential Across B-cell Malignancies8.12.2025 00:00:00 CET | Press release
Novel BCL2 inhibitor sonrotoclax monotherapy demonstrates deep and durable clinical responses in R/R MCL and R/R CLLSonrotoclax in combination with BRUKINSA demonstrated rapid MRD negativity in treatment-naive CLL, regardless of high-risk features BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data on sonrotoclax, a next-generation investigational BCL2 inhibitor, demonstrating meaningful clinical benefit as monotherapy and in combination across B-cell malignancies. These data were featured at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition in Orlando, Florida. The five presentations highlight durable responses in heavily pretreated patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) and additional studies showing deep, rapid, and sustained undetectable minimal residual disease (uMRD) rates with sonrotoclax-based combinations in patients with treatment-naive chronic lymphocytic leukemi
Andersen Consulting tilføjer samarbejdsfirmaet Codezilla7.12.2025 21:19:00 CET | Pressemeddelelse
Andersen Consulting styrker sine kompetencer inden for digital transformation gennem en samarbejdsaftale med Codezilla, et firma med hovedsæde i Rumænien, der udvikler specialtilpasset software. Codezilla specialiserer sig i at udvikle skræddersyede softwareprodukter, der løser forretningsmæssige udfordringer gennem en tværfaglig tilgang, som kombinerer softwareudvikling med dybdegående marketingekspertise. Med over 30 år på markedet fungerer firmaet som implementerings- og digital konsulentressource for reklamebureauer, samtidig med at de arbejder med en bred kundebase, herunder virksomheder inden for sundhedssektoren og medicinsk udstyr. Codezillas interne teams strækker sig over teknik, design og strategi og leverer omnichannel-løsninger til både regionale og globale kunder. "Vi tror på, at fantastisk software er resultatet af solid ingeniørkunst og disciplineret eksekvering," udtaler Sebastian Doroftei, administrerende direktør for Codezilla. "Vores samarbejde med Andersen Consulti
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release
Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
